Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

France Implements New Early Access Pathway For Innovative Medicines

Current Procedures Have Become Too Complex, Says Health Ministry

Executive Summary

Reforms to the French early access processes will make reimbursement decisions more predictable and bring greater consistency into the medicinal product pathway says the French pharmaceutical industry body Leem. Others, though, say the system is too complicated and lacks clarity in a number of areas.

You may also be interested in...



UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England

It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.

EU ‘Among World Leaders’ In COVID-19 Vaccination

Vaccination campaigns against the coronavirus in the EU are recovering ground lost in the early days of the pandemic, although the European Commission says “we need to keep up the effort.”

Coronavirus Notebook: EU Industry Claims ‘Undeniable’ Role Of IP, UK Targets Younger At-Risk Groups For Vaccination

Draft EU legislation on tackling cross-border health threats has taken another step forward, as health authorities say the Delta variant of the SARS-CoV-2 virus will be the “globally dominant strain” over the coming months.

Topics

UsernamePublicRestriction

Register

PS144584

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel